Eton Pharmaceuticals (ETON) Income towards Parent Company (2018 - 2026)

Eton Pharmaceuticals has disclosed Income towards Parent Company across 9 years of filings, most recently posting $11.6 million for Q2 2026.

• In Q2 2026, Income towards Parent Company rose 547.89% year-over-year to $11.6 million; the TTM figure through Jun 2026 stood at $9.5 million (up 293.81% YoY), while the FY2025 annual figure was -$3.6 million, up 22.09% from the prior year.
• Income towards Parent Company came in at $11.6 million for Q2 2026 at Eton Pharmaceuticals, up from $2.5 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $11.6 million in Q2 2026 to a low of -$5.3 million in Q1 2022.
• Average Income towards Parent Company over 5 years is -$276941.2, with a median of -$1.6 million recorded in 2022.
• Year-over-year, Income towards Parent Company slumped 407.34% in 2025 and surged 547.89% in 2026.
• Over 5 years, Income towards Parent Company stood at $2.8 million in 2022, then tumbled by 180.4% to -$2.3 million in 2023, then soared by 38.08% to -$1.4 million in 2024, then jumped by 277.74% to $2.5 million in 2025, then soared by 366.29% to $11.6 million in 2026.
• Per Business Quant data, the three most recent Income towards Parent Company figures were $11.6 million in Q2 2026, $2.5 million in Q4 2025, and -$1.9 million in Q3 2025.